BR112019003427A2 - compostos antibióticos - Google Patents

compostos antibióticos

Info

Publication number
BR112019003427A2
BR112019003427A2 BR112019003427-7A BR112019003427A BR112019003427A2 BR 112019003427 A2 BR112019003427 A2 BR 112019003427A2 BR 112019003427 A BR112019003427 A BR 112019003427A BR 112019003427 A2 BR112019003427 A2 BR 112019003427A2
Authority
BR
Brazil
Prior art keywords
compounds
infections
antibiotic compounds
gram
treatment
Prior art date
Application number
BR112019003427-7A
Other languages
English (en)
Inventor
Paul Meo Dr
Nawaz Khan Dr.
Original Assignee
Discuva Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Discuva Ltd. filed Critical Discuva Ltd.
Publication of BR112019003427A2 publication Critical patent/BR112019003427A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

a presente invenção refere-se a compostos antibióticos de fórmula (i), para composições contendo estes compostos e a métodos de tratamento de doenças bacterianas e infecções utilizando os compostos. os compostos encontram aplicação no tratamento de infecções e de doenças causadas por bactérias gram-positivas e / ou gram-negativas e, em particular, no tratamento de infecções e doenças causadas por neisseria gonorrhoeae.
BR112019003427-7A 2016-08-22 2017-08-22 compostos antibióticos BR112019003427A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1614314.1 2016-08-22
GBGB1614314.1A GB201614314D0 (en) 2016-08-22 2016-08-22 Antibiotic compounds
PCT/GB2017/052478 WO2018037223A1 (en) 2016-08-22 2017-08-22 Antibiotic compounds

Publications (1)

Publication Number Publication Date
BR112019003427A2 true BR112019003427A2 (pt) 2019-05-21

Family

ID=57045563

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112019003427-7A BR112019003427A2 (pt) 2016-08-22 2017-08-22 compostos antibióticos

Country Status (15)

Country Link
US (1) US20190194179A1 (pt)
EP (1) EP3500567A1 (pt)
JP (1) JP2019528291A (pt)
KR (1) KR20190046894A (pt)
CN (1) CN109923111A (pt)
AU (1) AU2017316742A1 (pt)
BR (1) BR112019003427A2 (pt)
CA (1) CA3034000A1 (pt)
CO (1) CO2019002624A2 (pt)
EA (1) EA201990551A1 (pt)
GB (1) GB201614314D0 (pt)
MX (1) MX2019001978A (pt)
PH (1) PH12019500360A1 (pt)
SG (1) SG11201901374WA (pt)
WO (1) WO2018037223A1 (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3636645A1 (de) 2018-10-11 2020-04-15 Bayer Aktiengesellschaft Verfahren zur herstellung schwefel-substituierter pyridinderivate
KR20210074318A (ko) 2018-10-11 2021-06-21 바이엘 악티엔게젤샤프트 이미다졸 유도체의 제조 방법
KR20210118840A (ko) 2019-01-24 2021-10-01 다이이찌 산쿄 가부시키가이샤 치환기를 갖는 우레아 화합물
CA3130739A1 (en) * 2019-02-22 2020-08-27 Anifera Limited Compositions providing enhanced antibacterial activity against gram-positive bacteria and use thereof
CN111808093B (zh) * 2019-04-12 2023-05-16 中国医学科学院医药生物技术研究所 一种新德里金属-β-内酰胺酶-1抑制剂
BR112021020055A2 (pt) * 2019-04-12 2021-12-07 Mitobridge Inc Indutores de hmox1
CN113185475A (zh) * 2021-04-29 2021-07-30 江苏永凯化学有限公司 一种高效低污染的精恶唑禾草灵生产工艺
WO2023234970A1 (en) * 2022-06-01 2023-12-07 KUDA Therapeutics, Inc. Imidazopyridine and oxazolopyridine derivatives and analogs thereof, methods of preparation thereof, methods of hif-1/2a pathway inhibition, and induction of ferroptosis
CN117003710A (zh) * 2023-07-19 2023-11-07 镇江先锋植保科技有限公司 一种2-巯基-6-氯苯并恶唑的制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8604217B2 (en) * 2009-11-12 2013-12-10 Selvita S.A. Compound, a process for its preparation, a pharmaceutical composition, use of a compound, a method for modulating or regulating serine/threonine kinases and a serine/threonine kinases modulating agent
JP5786402B2 (ja) * 2011-03-29 2015-09-30 コニカミノルタ株式会社 光学フィルム、及びそれを用いた偏光板、液晶表示装置
WO2016039939A1 (en) * 2014-09-09 2016-03-17 Ptc Therapeutics, Inc. Bicyclic and tricyclic substituted 2-pyridinone antibacterial compounds

Also Published As

Publication number Publication date
KR20190046894A (ko) 2019-05-07
US20190194179A1 (en) 2019-06-27
CO2019002624A2 (es) 2019-05-31
EP3500567A1 (en) 2019-06-26
SG11201901374WA (en) 2019-03-28
AU2017316742A1 (en) 2019-04-11
EA201990551A1 (ru) 2019-12-30
CN109923111A (zh) 2019-06-21
JP2019528291A (ja) 2019-10-10
MX2019001978A (es) 2019-08-01
CA3034000A1 (en) 2018-03-01
WO2018037223A1 (en) 2018-03-01
PH12019500360A1 (en) 2019-11-11
GB201614314D0 (en) 2016-10-05

Similar Documents

Publication Publication Date Title
BR112019003427A2 (pt) compostos antibióticos
PH12016501577A1 (en) Monobactam organic compounds for the treatment of bacterial infections
BR112018068593A2 (pt) composições tópicas não aquosas que compreendem uma salicilanilida halogenada
MX2016009898A (es) Tratamientos para acne resistente.
PH12017501019A1 (en) Isoxazole hydromaxamic acid compounds as lpxc inhibitors
MX2018001075A (es) Agentes terapeuticos y profilacticos antibacterianos.
CL2017002176A1 (es) Identificación bacteriana y prueba de susceptibilidad antimicrobiana.
NZ724798A (en) Polymyxin derivatives as antimicrobial compounds
ZA202002093B (en) Antibacterial compounds
MX2017012545A (es) Compuestos heterociclicos y su uso en la prevencion o tratamiento de las infecciones bacterianas.
BR112016016853A2 (pt) Compostos contendo nitrogênio, seu uso e seu processo de preparação, composição farmacêutica e seu uso
BR112014004704A2 (pt) compostos antibacterianos e métodos de uso
PH12016501988A1 (en) Antibacterial compounds
MX2017009094A (es) Derivado de polimixina y usos del mismo.
MX2017012073A (es) Compuestos de minociclina para biodefensas.
BR112018011670A2 (pt) compostos antibacterianos
BR112019024549A2 (pt) compostos derivados de glicopeptídeo e usos dos mesmos
WO2015024021A3 (en) Antibacterial compounds
BR112017023359A2 (pt) ?compostos, composições farmacêuticas e kits?
PH12016501532A1 (en) Antibacterial combinations comprising polymyxin
BR112019023130A2 (pt) Compostos e métodos para tratamento de infecções bacterianas
BR112022005345A2 (pt) Composições imunogênicas
BR112017022796A2 (pt) composições antibacterianas e métodos
EA201892278A1 (ru) Анбитактериальные биароматические производные с оксетан-3-илокси замещением
BR112018014082A2 (pt) tratamento para microrganismos contendo quitina

Legal Events

Date Code Title Description
B10A Cessation: cessation confirmed
B350 Update of information on the portal [chapter 15.35 patent gazette]